Skip to content
OpenCapital
Get started

Revolution Medicines, Inc. RVMD Q4 2025 Annual earnings

Reported February 25, 2026 · After market close

Revenue-Miss by $3.7MDiluted EPS-$1.86Miss by $0.28
Revenue estimate$3.7M
EPS estimate-$1.58

Next report

Aug 5, 2026 (In 3 weeks)
Revenue estimate$17.8M
EPS estimate-$1.96

Financials

Q4 2025

Income statement

See full
Revenue-—
Operating income-$361.6M-67.2%
Net income-$364.9M-87.5%
EPS (diluted)-$1.89-67.3%

Balance sheet

See full
Cash & equivalents$383.7M-29.3%
Total debt$158.7M+16.8%
Total equity$1.6B-28.0%
Total assets$2.4B-8.0%

Cash flow

See full
Operating cash flow-$274.2M-98.3%
CapEx$1.9M+57.5%
Free cash flow-$276.2M-97.9%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$15.4B+90.5%
Enterprise value$15.17B+97.7%

Returns & leverage

See full
Return on equity-58.1%+2,775pp
Debt / equity0.1×0.0×
Current ratio7.1×-7.1×

Versus estimates

Revenue

Q4 2024$261.6MBeat by $261.2M

Diluted EPS

Q1 2026-$2.29Miss by $0.46
Q4 2025-$1.86Miss by $0.28
Q3 2025-$1.61Miss by $0.19Q2 2025-$1.31Miss by $0.37Q1 2025-$1.13Miss by $0.01Q4 2024-$1.12Miss by $0.11

Ask the moment Revolution Medicines, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Revolution Medicines, Inc. report Q4 2025 earnings?
Revolution Medicines, Inc. (RVMD) reported Q4 2025 earnings on February 25, 2026 after market close.
What were Revolution Medicines, Inc.'s Q4 2025 revenue and EPS?
Revolution Medicines, Inc. reported revenue of - and diluted EPS of $-1.86 for Q4 2025.
Did Revolution Medicines, Inc. beat estimates in Q4 2025?
Revenue missed the consensus estimate of $3.7M by $3.7M. EPS missed the consensus estimate of $-1.58 by $0.28.
How did Revolution Medicines, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 100.0% from $261.6M a year earlier and diluted EPS declined 66.1% from $-1.12.
Where can I find Revolution Medicines, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-071517) and the 10-K periodic report (0001193125-26-071563) directly on SEC EDGAR. The filing index links above go to sec.gov.